Tesla
TSLA
MicroStrategy
MSTR
MARA Holdings
MARA
Apple
AAPL
Microsoft
MSFT
US Stock MarketDetailed Quotes
ICCM Icecure Medical
- 1.070
- +0.130+13.83%
Close Dec 13 16:00 ET
- 1.070
- 0.0000.00%
Post 20:02 ET
59.39MMarket Cap-3.82P/E (TTM)
1.100High0.970Low1.35MVolume0.983Open0.940Pre Close1.40MTurnover4.81%Turnover RatioLossP/E (Static)55.50MShares1.57052wk High5.91P/B30.00MFloat Cap0.48052wk Low--Dividend TTM28.04MShs Float16.000Historical High--Div YieldTTM13.79%Amplitude0.480Historical Low1.037Avg Price1Lot Size
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Icecure Medical Stock Forum
IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results
Thursday, 5th December at 8:30 am
Data confirm previous results showing that ProSense® cryoablation is highly effective for kidney tumors
$Infobird Software (IFBD.US)$ Completed $40M acquisition. China stock. Low float. 0 shares LTB✅
$Ocean Power Technologies (OPTT.US)$ Form 4 insider buying. 0 shares LTB✅
$T Stamp (IDAI.US)$ Ran today. Up after hours. Possible catalyst. Low float. 0 shares LTB✅
$Syra Health (SYRA.US)$ Recent Form 4s multiple insider loading. Low fl...
ProSense systems and disposable probe sales increased by 36% to $2.32 million for the nine months ending September 30, 2024, compared to the previous year.
Total revenue grew by 22% to $2.42 million in the same period, driven by higher sales in Europe, the US, and Japan.
Gross profit increased by 41% to $1.03 million, an...
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation
IceCure Medical reported strong financial results for the first nine months of 2024, with 36% growth in ProSense® system and probe sales to $2.3M.
Gross profits increased 41%, with non-GAAP gross profits up 104%.
Gross margins improved to 43% from 37% year-over-year.
The FDA Advisory Panel voted favorably for ProSense®'s benefit-risk prof...
$Poseida Therapeutics (PSTX.US)$ ✔️TOP PLAY. To be acquired by Roche for $1.5B for $9.00/share. “Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 per share in cash”
$Citius Pharmaceuticals (CTXR.US)$✔️ News halt after hours + PR today o...
IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office
IceCure Medical (NASDAQ: ICCM) has received a Notice of Allowance from Japan's Patent Office for its 'Cryogenic System with Multiple Submerged Pumps' invention. This technology enables a next-generation MSense™ multiprobe cryoablation system that can independently control multiple cryoprobes for treating larger tumors. The patent strengthens IceCure's ...
Icecure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance From Japan's Patent Office
Benzinga· 3 mins ago
PRECICE study, financed by the Umberto Veronesi Foundation and the Italian Ministry of Health, is led by multidisciplinary collaborators including breast surgeons, interventional radiologists, and breast imaging and pathology specialists
PRECICE is exclusively using ProSense to treat all 233 Lu...
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health
IceCure Medical's ProSense® has been selected for the PRECICE study, a major breast cryoablation research initiative led by the European Institute of Oncology. The study, sponsored by the Umberto Veronesi Foundation and Italian Ministry of Health, will exclusively use ProSense® to treat 233 patients aged...
No comment yet